MX390786B - Métodos y composiciones para tratar somnolencia excesiva. - Google Patents

Métodos y composiciones para tratar somnolencia excesiva.

Info

Publication number
MX390786B
MX390786B MX2019014409A MX2019014409A MX390786B MX 390786 B MX390786 B MX 390786B MX 2019014409 A MX2019014409 A MX 2019014409A MX 2019014409 A MX2019014409 A MX 2019014409A MX 390786 B MX390786 B MX 390786B
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating excessive
excessive sleepiness
sleepiness
Prior art date
Application number
MX2019014409A
Other languages
English (en)
Spanish (es)
Other versions
MX2019014409A (es
Inventor
Lawrence Patrick Carter
Yuan Lu
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64455104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX390786(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2019014409A publication Critical patent/MX2019014409A/es
Publication of MX390786B publication Critical patent/MX390786B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
MX2019014409A 2017-06-02 2018-06-01 Métodos y composiciones para tratar somnolencia excesiva. MX390786B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514176P 2017-06-02 2017-06-02
PCT/US2018/035532 WO2018222954A1 (en) 2017-06-02 2018-06-01 Methods and compositions for treating excessive sleepiness

Publications (2)

Publication Number Publication Date
MX2019014409A MX2019014409A (es) 2022-03-17
MX390786B true MX390786B (es) 2025-03-21

Family

ID=64455104

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014409A MX390786B (es) 2017-06-02 2018-06-01 Métodos y composiciones para tratar somnolencia excesiva.

Country Status (12)

Country Link
US (7) US10959976B2 (https=)
EP (1) EP3630072A4 (https=)
JP (1) JP2020528075A (https=)
KR (3) KR102726728B1 (https=)
CN (1) CN111201014A (https=)
AU (1) AU2018278332B2 (https=)
BR (1) BR112019025286A2 (https=)
CA (1) CA3065522A1 (https=)
MX (1) MX390786B (https=)
MY (1) MY203401A (https=)
PH (1) PH12019502723A1 (https=)
WO (1) WO2018222954A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2021001457A1 (en) * 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
MX2024002483A (es) * 2021-09-03 2024-03-14 Axsome Therapeutics Metodos y composiciones para mejorar biomarcadores asociados con riesgo cardiovascular usando carbamato de (r)-2-amino-3-fenilpropi lo.
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
AU2023375326A1 (en) * 2022-11-07 2025-05-22 Axsome Therapeutics Compositions and methods for treating insomnia
WO2024118904A1 (en) * 2022-11-30 2024-06-06 Axsome Therapeutics Methods and compositions for improving driving performance
US11771666B1 (en) 2022-12-30 2023-10-03 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12064411B1 (en) * 2022-12-30 2024-08-20 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12036194B1 (en) 2022-12-30 2024-07-16 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12090126B2 (en) 2022-12-30 2024-09-17 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
CN120641090A (zh) * 2022-12-30 2025-09-12 阿克苏姆马耳他有限公司 向哺乳期女性施用索安非托的方法
US12102609B2 (en) 2022-12-30 2024-10-01 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12005036B1 (en) 2022-12-30 2024-06-11 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
EP4719375A1 (en) * 2023-05-30 2026-04-08 Axsome Therapeutics, Inc. Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases
WO2025064549A1 (en) * 2023-09-18 2025-03-27 Axsome Therapeutics, Inc. Solriamfetol for improving cognitive health in apnea patients

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
DE9311004U1 (de) 1993-07-23 1993-10-14 Mauser-Werke GmbH, 50321 Brühl Palettencontainer
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
ES2262826T3 (es) 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato en la prevencion o el tratamiento de transtornos de ansiedad.
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
MXPA03007717A (es) 2001-02-27 2005-11-08 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
CA2494233A1 (en) 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
EP2566462B1 (en) 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP2392325A1 (en) 2010-06-04 2011-12-07 Universitätsklinikum Münster Compounds for the prevention and/or treatment of osteoarthrosis
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
CN110638805A (zh) 2013-07-12 2020-01-03 爵士制药国际Iii有限公司 促进吸烟停止
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Also Published As

Publication number Publication date
KR102726728B1 (ko) 2024-11-05
BR112019025286A2 (pt) 2020-06-23
KR20200016889A (ko) 2020-02-17
US11865098B1 (en) 2024-01-09
US10959976B2 (en) 2021-03-30
US11648232B2 (en) 2023-05-16
US20240180866A1 (en) 2024-06-06
PH12019502723A1 (en) 2020-07-13
EP3630072A4 (en) 2021-03-10
US20200281886A1 (en) 2020-09-10
AU2018278332A1 (en) 2020-01-30
EP3630072A1 (en) 2020-04-08
CN111201014A (zh) 2020-05-26
MX2019014409A (es) 2022-03-17
JP2020528075A (ja) 2020-09-17
WO2018222954A1 (en) 2018-12-06
NZ760594A (en) 2025-05-02
US20250114322A1 (en) 2025-04-10
US20210205257A1 (en) 2021-07-08
CA3065522A1 (en) 2018-12-06
AU2018278332B2 (en) 2022-05-19
US20240189270A1 (en) 2024-06-13
KR20240162165A (ko) 2024-11-14
US10912754B2 (en) 2021-02-09
US20200163927A1 (en) 2020-05-28
MY203401A (en) 2024-06-26
KR20230145525A (ko) 2023-10-17
US20240033243A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MX390786B (es) Métodos y composiciones para tratar somnolencia excesiva.
SA521422063B1 (ar) تركيبات وطرق لتعديل نشاط ديهيدروجيناز بسلسلة قصيرة
EA201890641A3 (ru) Стимуляторы sgc
MX388693B (es) Composiciones de nanoparticulas para terapia sostenida.
UY38670A (es) Inhibidores de dihidroorotato deshidrogenasa
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
MX366681B (es) Composiciones de gamma-hidroxibutirato y sus usos para el tratamiento de trastornos.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MY180626A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
BR112022004576A2 (pt) Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
JOP20220317A1 (ar) تركيبات وطرق لتعديل نشاط ديهيدروجيناز بسلسلة قصيرة
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
BR112018006445A2 (pt) métodos para tratar distrofia muscular
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
MX2020001146A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
EP4345110A3 (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
GEP20247644B (en) Inhibitors of adrenoreceptor adrac2
AU2017379247A8 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2015009696A (es) Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.